Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | AHCY | P23526 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386366 | 1.00 | ADORA3 (0.57) | ADORA3TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL9386714 | 0.83 | ADORA3 (0.43) | ADORA3TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL3254318 | 0.83 | ADORA2A (0.50) | ADORA3ADORA2AADORA2BADORA1AHCY | |
| SCHEMBL9388463 | 0.82 | ADORA3 (0.81) | ADORA3TSHRADORA2AADORA2BTP53 | |
| SCHEMBL3253858 | 0.82 | ADORA3 (0.81) | ADORA3TSHRADORA2AADORA2BTP53 | |
| SCHEMBL9567830 | 0.77 | ADORA3 (0.41) | ADORA3TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL3252258 | 0.77 | ADORA3 (0.47) | ADORA3TSHRADORA2AADORA2BADORA1 | |
| SCHEMBL25173722 | 0.77 | SLC29A1 (0.57) | ADORA3ADORA2AADORA1TP53SLC29A1 | |
| SCHEMBL25173742 | 0.77 | SLC29A1 (0.57) | ADORA3ADORA2AADORA1TP53SLC29A1 | |
| SCHEMBL25176536 | 0.76 | ADORA3 (0.57) | ADORA3ADORA2AADORA2BADORA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | claimed |
| EP-0896063-B9 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| EP-0896063-B1 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |